Ono licenses rare blood disease drug from Ionis for $280M upfront

Ono Pharmaceutical is spending $280 million upfront to take the global rights of Ionis Pharmaceuticals’ asset for a rare blood disorder, marking the latest partnership …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Nudges seem to have no effect in motivating people to get vaccinated

One popular strategy to motivate people to get vaccinated is the nudge-;a message designed to take advantage of human tendencies to conform to social norms,

August 6, 2024

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder | Psychedelic Invest

TORONTO, November 18, 2024–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company“), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing

November 18, 2024

New liquid biopsy technology uses RNA “dark matter” to detect cancer

Cancer is most treatable in its early stages, so finding innovative and non-invasive methods to diagnose cancer early on is crucial for fighting the disease.

August 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.